Rare Solid Cancers: An Introduction

Chairs: P.G. Casali, IT - G. Gatta, IT

COURSE OUTLINE
Rare cancers are frequent. In fact, being so many, they are rare individually, but not collectively. As many as 15% of cancer cases are made up of rare solid cancers of the adult. It follows that clinical oncologists see several patients with these cancers in their everyday practice. This is the reason to focus on them in an educational course, which was organized by a clinician and an epidemiologist.

In two days, all main rare solid cancers of the adult will be dealt with by clinical experts, with whom the audience will be able to interact. However, rare cancers also present peculiar problems, for example under the perspective of organization of care and methodology of clinical studies. These aspects will be dealt with as well, to give those who wish to specialize in rare cancers food for thought. More and more, indeed, many of these issues affect frequent cancers too, as long as the heterogeneity of molecular targets makes these a blend of a number of subtypes.

Medical oncologists, and more generally all clinical oncologists, will be interested, but also epidemiologists and health administrators may find this area challenging for their practice. 

ORGANISING SECRETARIAT
Francesca Marangoni
European School of Oncology
Via del Bollo, 4
20123 Milan - Italy
Tel: +39 02 8546 4525
Fax: +39 02 8546 4545
Email: fmarangoni@eso.net


COURSE VENUE
Hotel Regina Palace
Corso Umberto I
28838 Stresa - Italy
Tel: +39 0323 936936
Fax: +39 0323 936666
Website: www.regina-palace.it
Email: sales@regina-palace.it

HOW TO REACH THE COURSE VENUE:

By car: from Milan, take the A8 highway, “Laghi - Sesto Calende - Varese” direction; then take the A26 highway, “Gravellona Toce” direction. Nearest way to Stresa: “Carpugnino”

By train: Stresa is- on the main railway Milan - Simplon - Geneva - Paris. The train station is within walking distance from the hotel. Taxis are usually available outside the train station.

By plane: The hotel is placed nearby the international airport of Milan Malpensa (45 km).
Take the A26 highway, “Gravellona Toce” direction up to the “Stresa” way out.


OFFICIAL LANGUAGE
The official language of the course will be English. No simultaneous translation will be provided.


ACCREDITATION AND CERTIFICATES
All participants will be issued with a certificate of attendance at the close of the course.
Application for CME recognition has been submitted to ESMO for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). In addition, for Italian doctors the application for ECM recognition will be submitted to the Commissione Nazionale per la Formazione Continua.
The event has been awarded by the ESMO ECWG with 10 ESMO-MORA cat.1 points.
Information on the status of the applications can be obtained from the organising secretariat.


BADGES
The badge is the only official evidence of registration and should be worn at all times during the course. Loss of badge means loss of registration.


INSURANCE
The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are strongly advised to take out their own personal and travel insurance coverage.


IMPORTANT DEADLINES 
07/03/2011  cancellation deadline
07/03/2011  replacement deadline
15/03/2011  registration deadline (after this date, registration will only be available onsite)

INVITED FACULTY

E. Baudin, Institut Gustave-Roussy, Dept. Nuclear Medicine and Endocrine Tumors, Villejiuf, FR
A. Berruti, Università degli Studi di Torino, Dept. Clinical and Biological Sciences, Turin, IT
J.Y. Blay, University Claude Bernard and Centre Léon Bérard, Dept. Medicine, Lyon, FR
P. Bruzzi, Istituto Nazionale per la Ricerca sul Cancro, Dept. Epidemiology and Prevention, Genoa, IT
P.G. Casali, Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. Cancer Medicine, Milan, IT
S. Cascinu, Ospedali Riuniti, University of Marche, Medical Oncology Clinic, Ancona, IT
A.P. Dei Tos, Ospedale S. Maria di Ca' Foncello, Dept. of Pathology, Treviso, IT
A. Ferrari, Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. Cancer Medicine, Milan, IT
G. Gatta, Fondazione IRCCS Istituto Nazionale dei Tumori, Evaluative Epidemiology Unit, Milan, IT
J. Geissler, Co-founder, CML Advocates Network, Riemerling, DE 
A. Gronchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. Surgery, Milan, IT
V. Kataja, Vaasa Central Hospital, Vaasa and Kuopio University, Kuopio, FL
L. Licitra, Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. Cancer Medicine, Milan, IT
I. Ray-Coquard, Centre Léon Bérard, Dept. Medical Oncology, Lyon, FR
K. Redmond, Cancer World Editor, Lugano, CH
G. Rosti, Ospedale S. Maria di Ca' Foncello, Dept. Oncology, Treviso, IT
P. Schoffski, University Hospital Gasthuisberg, Department of General Medical Oncology, Leuven, BE
R. Soffietti,  University Hospital Molinette, Dept. Oncology, Turin, IT
R.A. Stahel, University Hospital Zurich, Clinic and Policlinic for Oncology, Zurich, CH

31 March

1 April